Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) in countries where the product ...
Pharmabiz3d
Santhera enters supply and distribution agreement with Clinigen Group for Agamree to treat patients with Duchenne muscular dystrophy
Pratteln, Switzerland Tuesday, January 7, 2025, 11:00 Hrs [IST] ...
Santhera Pharmaceuticals Holding AG: Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) ...
FiercePharma16h
Catalyst settles with Teva, staving off Firdapse generic until 2035
Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...
Zacks.com on MSN16h
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced ...
pharmaphorum4d
Price deal opens door to NHS use of Santhera DMD drug
Santhera's Duchenne muscular dystrophy (DMD) therapy Agamree has been cleared for NHS use after a confidential pricing agreement. The deal means that Agamree (vamorolone) will be available to ...
The Pharma Letter3d
Santhera partners with Clinigen to expand Agamree access
Santhera partners with Clinigen to supply Agamree for Duchenne muscular dystrophy in regions without commercial availability.
pharmaphorum6d
Capricor files cell therapy for DMD cardiomyopathy with FDA
Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...
manilatimes4d
NMD Pharma Announces FDA Orphan Drug Designation Granted to NMD670 for the Treatment of Patients with Charcot-Marie-Tooth Disease
This is the 2 nd orphan drug designation granted to the skeletal muscle-specific drug therapy NMD670 Under this newly granted orphan drug designation, NMD670 is currently being evaluated in a Phase 2 ...
The New York Times1d
World News
After Donald Trump suggested he might take over Greenland by force, the consensus among the island’s population appears to be bewilderment and anxiety. By Jeffrey Gettleman and Maya Tekeli ...
The New York Times1d
World News
After Donald Trump suggested he might take over Greenland by force, the consensus among the island’s population appears to be bewilderment and anxiety. By Jeffrey Gettleman and Maya Tekeli The ...